Jermasek Douglas 4/A

What Happened

• Douglas Jermasek, Executive Vice President, Corporate Strategy of Unicycive Therapeutics (UNCY), was granted 169,500 restricted stock units (RSUs) on May 14, 2026. The RSUs are recorded at $0.00 per share (an equity award rather than a purchase or sale) and will be settled in common stock according to a vesting schedule.

Key Details

• Transaction type: Award/Grant (code A) — derivative RSU award of 169,500 shares, price $0.00 (no cash exchanged at grant).
• Transaction date: 2026-05-14; this filing is an amendment filed 2026-06-15 (approx. one month after the transaction).
• Vesting: 23,542 shares vest immediately upon grant; 4,708 shares vest monthly over 31 months beginning June 1, 2026 (per footnote).
• Shares owned after transaction: Not disclosed in this filing.
• Footnote: Award payable solely in common stock and subject to continued service; no 10b5-1 plan, tax-withholding, or cashless exercise noted here.

Context

• This is a compensation grant (RSUs) rather than a market purchase or sale. RSU grants are common executive compensation and represent a future right to receive shares if vesting conditions are met; they do not necessarily indicate immediate buying or selling intent. The filing was amended about a month after the reported grant date.